Affimed N.V. (NASDAQ: AFMD)
$5.16
+0.0050 ( +0.10% ) 102.9K
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
Market Data
Open
$5.16
Previous close
$5.15
Volume
102.9K
Market cap
$77.66M
Day range
$5.00 - $5.45
52 week range
$2.24 - $8.95
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 1 | Jun 26, 2024 |
6-k | Quarterly Reports | 5 | Jun 12, 2024 |
6-k/a | Quarterly Reports | 3 | Jun 06, 2024 |
6-k | Quarterly Reports | 3 | Jun 03, 2024 |
6-k | Quarterly Reports | 8 | May 28, 2024 |
6-k | Quarterly Reports | 3 | May 23, 2024 |
20-f | Annual reports | 137 | Mar 28, 2024 |
6-k | Quarterly Reports | 3 | Mar 28, 2024 |
6-k | Quarterly Reports | 1 | Mar 11, 2024 |
6-k | Quarterly Reports | 3 | Mar 06, 2024 |